Everest Medicines Partners with Guangdong Provincial People’s Hospital in Kidney Disease Research
China-based Everest Medicines Ltd (HKG: 1952) has announced a comprehensive strategic partnership with Guangdong Provincial...
Sihuan Pharmaceutical’s KM501 Receives Clinical Trial Approval for HER2-Positive Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
4B Technologies’ FB1001 Receives CDE Approval for Clinical Trials
China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from...
RemeGen’s RC48 Receives Two Clinical Trial Approvals for Breast Cancer Treatments
RemeGen Ltd (HKG: 9995) has announced the receipt of two clinical trial approvals for its...
China’s Plan to Strengthen Medical and Healthcare Service System Unveiled
The General Office of the CPC Central Committee and State Council has released the “Opinions...
Alphax Bio Raises Millions for Spatial Proteomics and Tumor Immune Microenvironment Research
Beijing-based Alphax Bio, a developer of immune-testing technologies, has reportedly raised “tens of millions” of...
Luye Pharma’s Lurbinectedin Gains Priority Review Status for SCLC Treatment
The Center for Drug Evaluation (CDE) website indicates that China-based Luye Pharma Group’s (HKG: 2186)...
Guangdong Zhongsheng’s RAY1216 Receives Conditional Approval for COVID-19 Treatment
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received conditional...
Hengrui Pharmaceuticals’ HRS-5965 Receives NMPA Approval for Clinical Study in Hemolytic Anemia
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval...
Sunshine Guojian Completes Patient Enrollment for SSGJ-611 Phase II Study in Atopic Dermatitis
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...
Henlius Biotech’s Serplulimab Accepted for EMA Review for ES-SCLC Treatment
Shanghai Henlius Biotech (HKG: 2696) has announced that the European Medicines Agency (EMA) has accepted...
Sino Biopharmaceutical’s F-star Therapeutics Signs Second Licensing Deal with Takeda
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a second licensing agreement between its recently acquired...
AstraZeneca’s Calquence Receives Conditional Approval in China for MCL
AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received conditional market approval in China...
Biohaven Acquires Global Rights for Dual TYK2/JAK1 Inhibitor BHV-8000 from Highlightll
US-based Biohaven Ltd. (NYSE: BHVN) has announced the acquisition of global rights, excluding China regions,...
Hinova Pharmaceuticals’ HC-1119 NDA Accepted for Review by NMPA
Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the New Drug Application (NDA)...
Boehringer Ingelheim Initiates Phase III FIBRONEER Studies for PDE4B Inhibitor BI 1015550
German pharmaceutical giant Boehringer Ingelheim (BI) has announced the first patient enrollments in the Phase...
Grand Pharmaceutical Group Reports 15.1% Revenue Growth in 2022 Financials
China-based Grand Pharmaceutical Group Limited (HKG: 0512) published its 2022 financials, reporting revenues of HKD...
Ascentage Pharma’s 2022 Revenue Soars with Olverembatinib Sales
China-based Ascentage Pharma (HKG: 6855) has announced its 2022 financial results, marking the first year...
Ping An Good Doctor Reports Revenue Decline but Medical Services Growth in 2022
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...
JD Healthcare Reports 52.3% Revenue Growth in 2022 Financial Report
JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), released its 2022 financial...